PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
NBIX vs. UTHR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between NBIX and UTHR is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

NBIX vs. UTHR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Neurocrine Biosciences, Inc. (NBIX) and United Therapeutics Corporation (UTHR). The values are adjusted to include any dividend payments, if applicable.

-20.00%-10.00%0.00%10.00%20.00%AugustSeptemberOctoberNovemberDecember2025
-1.39%
7.91%
NBIX
UTHR

Key characteristics

Sharpe Ratio

NBIX:

0.14

UTHR:

2.19

Sortino Ratio

NBIX:

0.39

UTHR:

2.90

Omega Ratio

NBIX:

1.06

UTHR:

1.40

Calmar Ratio

NBIX:

0.17

UTHR:

2.48

Martin Ratio

NBIX:

0.36

UTHR:

11.43

Ulcer Index

NBIX:

12.56%

UTHR:

5.38%

Daily Std Dev

NBIX:

32.84%

UTHR:

28.02%

Max Drawdown

NBIX:

-97.21%

UTHR:

-93.18%

Current Drawdown

NBIX:

-6.46%

UTHR:

-12.46%

Fundamentals

Market Cap

NBIX:

$14.50B

UTHR:

$16.36B

EPS

NBIX:

$3.78

UTHR:

$22.29

PE Ratio

NBIX:

37.90

UTHR:

16.10

PEG Ratio

NBIX:

0.33

UTHR:

1.43

Total Revenue (TTM)

NBIX:

$1.73B

UTHR:

$2.14B

Gross Profit (TTM)

NBIX:

$1.69B

UTHR:

$1.91B

EBITDA (TTM)

NBIX:

$458.00M

UTHR:

$1.18B

Returns By Period

In the year-to-date period, NBIX achieves a 4.95% return, which is significantly higher than UTHR's 1.73% return. Over the past 10 years, NBIX has outperformed UTHR with an annualized return of 16.34%, while UTHR has yielded a comparatively lower 9.40% annualized return.


NBIX

YTD

4.95%

1M

5.79%

6M

-1.39%

1Y

4.29%

5Y*

6.76%

10Y*

16.34%

UTHR

YTD

1.73%

1M

0.39%

6M

9.04%

1Y

63.81%

5Y*

31.06%

10Y*

9.40%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

NBIX vs. UTHR — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NBIX
The Risk-Adjusted Performance Rank of NBIX is 4848
Overall Rank
The Sharpe Ratio Rank of NBIX is 5151
Sharpe Ratio Rank
The Sortino Ratio Rank of NBIX is 4242
Sortino Ratio Rank
The Omega Ratio Rank of NBIX is 4545
Omega Ratio Rank
The Calmar Ratio Rank of NBIX is 5454
Calmar Ratio Rank
The Martin Ratio Rank of NBIX is 5050
Martin Ratio Rank

UTHR
The Risk-Adjusted Performance Rank of UTHR is 9292
Overall Rank
The Sharpe Ratio Rank of UTHR is 9494
Sharpe Ratio Rank
The Sortino Ratio Rank of UTHR is 9191
Sortino Ratio Rank
The Omega Ratio Rank of UTHR is 9191
Omega Ratio Rank
The Calmar Ratio Rank of UTHR is 9393
Calmar Ratio Rank
The Martin Ratio Rank of UTHR is 9393
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NBIX vs. UTHR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and United Therapeutics Corporation (UTHR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for NBIX, currently valued at 0.14, compared to the broader market-2.000.002.004.000.142.19
The chart of Sortino ratio for NBIX, currently valued at 0.39, compared to the broader market-4.00-2.000.002.004.000.392.90
The chart of Omega ratio for NBIX, currently valued at 1.06, compared to the broader market0.501.001.502.001.061.40
The chart of Calmar ratio for NBIX, currently valued at 0.17, compared to the broader market0.002.004.006.000.172.48
The chart of Martin ratio for NBIX, currently valued at 0.36, compared to the broader market-10.000.0010.0020.0030.000.3611.43
NBIX
UTHR

The current NBIX Sharpe Ratio is 0.14, which is lower than the UTHR Sharpe Ratio of 2.19. The chart below compares the historical Sharpe Ratios of NBIX and UTHR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.00AugustSeptemberOctoberNovemberDecember2025
0.14
2.19
NBIX
UTHR

Dividends

NBIX vs. UTHR - Dividend Comparison

Neither NBIX nor UTHR has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

NBIX vs. UTHR - Drawdown Comparison

The maximum NBIX drawdown since its inception was -97.21%, roughly equal to the maximum UTHR drawdown of -93.18%. Use the drawdown chart below to compare losses from any high point for NBIX and UTHR. For additional features, visit the drawdowns tool.


-25.00%-20.00%-15.00%-10.00%-5.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-6.46%
-12.46%
NBIX
UTHR

Volatility

NBIX vs. UTHR - Volatility Comparison

The current volatility for Neurocrine Biosciences, Inc. (NBIX) is 5.90%, while United Therapeutics Corporation (UTHR) has a volatility of 8.17%. This indicates that NBIX experiences smaller price fluctuations and is considered to be less risky than UTHR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%AugustSeptemberOctoberNovemberDecember2025
5.90%
8.17%
NBIX
UTHR

Financials

NBIX vs. UTHR - Financials Comparison

This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and United Therapeutics Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab